Finerenone (Kerendia)
Details
Finerenone (brand name Kerendia; Bayer) is a nonsteroidal selective mineralocorticoid receptor antagonist (MRA). Unlike steroidal MRAs (spironolactone, eplerenone), finerenone has greater MR selectivity with no off-target binding to androgen, glucocorticoid, or progesterone receptors — reducing sex hormone-related adverse effects. It has a shorter half-life and no active metabolites. Initially approved for CKD with type 2 diabetes (FIDELIO-DKD, FIGARO-DKD); FINEARTS-HF (NEJM 2024) established its benefit in HFmrEF/HFpEF.
Key Facts
Mechanism of Action
- Blocks the mineralocorticoid receptor, reducing aldosterone-mediated sodium retention, fluid overload, sympathetic activation, cardiac and renal fibrosis, and inflammation. (sources/finerenone-hfpef-fineartshf-nejm-2024 — very high)
- Greater MR selectivity vs spironolactone → no androgenic side effects (gynecomastia, sexual dysfunction). (sources/finerenone-hfpef-fineartshf-nejm-2024 — very high)
- Distinct physicochemical properties from steroidal MRAs: non-steroidal scaffold, no active metabolites, shorter half-life. (sources/finerenone-hfpef-fineartshf-nejm-2024 — very high)
Dosing and Administration
- HF with LVEF ≥40%: Individualized based on eGFR and potassium; maximum 20 mg OD (eGFR ≥60) or 40 mg OD (eGFR ≥25 to <60).
- Requires regular monitoring of serum potassium and renal function.
- Contraindicated when K+ >5 mmol/L at initiation; close monitoring essential. (sources/finerenone-hfpef-fineartshf-nejm-2024 — very high)
Clinical Trials
FINEARTS-HF (HFmrEF/HFpEF; NEJM 2024)
- Phase 3 double-blind RCT; n=6,001; 654 sites; 37 countries; median 32 months.
- Primary composite (total worsening HF events + CV death): Rate ratio 0.84 (95% CI 0.74–0.95; P=0.007) — first MRA to achieve a positive primary endpoint in HFmrEF/HFpEF.
- Total worsening HF events (secondary): Rate ratio 0.82 (95% CI 0.71–0.94; P=0.006).
- CV death: HR 0.93 (95% CI 0.78–1.11) — NOT significant.
- All-cause death: HR 0.93 (95% CI 0.83–1.06) — NOT significant.
- KCCQ total symptom score: +1.6 points improvement (95% CI 0.8–2.3; P<0.001) — statistically significant but below 5-point MCID.
- NYHA functional class improvement: OR 1.01 (95% CI 0.88–1.15) — NOT significant.
- Kidney composite: HR 1.33 (95% CI 0.94–1.89) — NOT significant; numerically higher.
- Hyperkalemia (K+ >6 mmol/L): 3.0% vs 1.4%; no deaths; 0.5% vs 0.2% hospitalizations.
- Hypokalemia: Reduced with finerenone.
- Benefit consistent in patients on/off baseline SGLT2 inhibitors. (sources/finerenone-hfpef-fineartshf-nejm-2024 — very high)
CKD + Type 2 Diabetes Trials
- FIDELIO-DKD and FIGARO-DKD: Finerenone reduced kidney disease progression and CV events (including HF hospitalization) in patients with CKD and T2DM. These data supported its initial approval for CKD. (sources/finerenone-hfpef-fineartshf-nejm-2024 — very high)
Approved Indications
- Chronic kidney disease (CKD) with type 2 diabetes — to reduce risk of kidney disease progression and CV events.
- Heart failure with LVEF ≥40% (HFmrEF and HFpEF) — based on FINEARTS-HF.
Contradictions / Open Questions
- No direct comparison with spironolactone in HFpEF: TOPCAT (spironolactone) vs FINEARTS-HF (finerenone) differ in drug, endpoint methodology (time-to-first vs total events), background therapy, follow-up, and data integrity — it cannot be concluded that finerenone is superior to spironolactone in HFpEF. (sources/finerenone-hfpef-fineartshf-nejm-2024 — very high)
- No mortality benefit despite significant primary endpoint: CV death (HR 0.93; NS) and all-cause death (HR 0.93; NS) were both non-significant. The primary composite benefit is driven entirely by HF hospitalization reduction — finerenone joins SGLT2i as a class of agents that reduce HF events but not mortality in HFmrEF/HFpEF. (sources/finerenone-hfpef-fineartshf-nejm-2024 — very high)
- Kidney composite numerically worse (HR 1.33) unlike CKD-T2DM trials: Nephroprotective signal from FIDELIO-DKD/FIGARO-DKD does not appear to replicate in HFpEF patients who have low albuminuria and minimal kidney disease burden — the nephroprotective mechanism may be albuminuria/CKD-dependent. (sources/finerenone-hfpef-fineartshf-nejm-2024 — very high)
- KCCQ improvement is statistically significant but clinically marginal (+1.6 points vs 5-point MCID): The trial was powered for the event-based primary endpoint; the KCCQ improvement is statistically robust but its clinical meaningfulness to individual patients is questionable. This mirrors the challenge across HFpEF trials where symptom improvement is modest. (sources/finerenone-hfpef-fineartshf-nejm-2024 — very high)
- Additive benefit on top of SGLT2i not established: While benefit was consistent in SGLT2i users (13.6% at baseline), the trial was not powered to formally confirm additive benefit and the combination of two HF-hospitalization-reducing agents without mortality benefit raises the question of whether combination use offers clinically meaningful incremental gains. (sources/finerenone-hfpef-fineartshf-nejm-2024 — very high)
Connections
- Related to entities/HFpEF — primary disease target; first MRA with positive primary endpoint in this population
- Related to entities/Heart-Failure — overarching HF framework
- Related to entities/HFrEF — context: steroidal MRAs (RALES, EMPHASIS-HF) established in HFrEF
- Related to concepts/Cardiorenal-Syndrome — kidney composite; divergent nephroprotective signals
- Related to sources/spironolactone-hfpef-topcat-nejm-2014 — prior MRA attempt in HFpEF